Steroid preservation: the rationale for continued prescribing

被引:7
作者
Marks, SD [1 ]
Trompeter, RS [1 ]
机构
[1] Great Ormond St Hosp Sick Children, NHS Trust, Dept Paediat Nephrol, London WC1N 3JH, England
关键词
corticosteroid; immunosuppression; infection; PTLD; rejection; transplantation;
D O I
10.1007/s00467-005-2155-7
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Tailored immunosuppression according to risk stratification for optimal outcome for both immunological and non-immunological risk factors should be the ultimate objective for every child in whom renal transplantation is planned. Renal allograft survival is dependent on the appropriate use of immunosuppressive therapy to prevent acute rejection and chronic allograft nephropathy. Unfortunately, all immunosuppressive therapies, including corticosteroids, have unwanted side effects, including infections, malignancy, nephrotoxicity, hypertension, hyperlipidaemia and diabetes mellitus. However, the most worrying side effects of corticosteroids for children, adolescents and their parents are growth retardation and the cosmetic effects. Consequently, achieving immunosuppressive regimens without corticosteroids would be preferable. The major concern for paediatric nephrologists in the 21st century is no longer acute rejection, as the incidence appears to be decreasing, but infection, particularly EBV and the development of post-transplant lymphoproliferative disease (PTLD). With modern immunosuppressive agents in transplantation, rejection is being traded for infection. The long-term outcome data of PTLD with steroid-free and monoclonal antibody protocols is as yet unknown.
引用
收藏
页码:305 / 307
页数:3
相关论文
共 16 条
[1]   Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study [J].
Benfield, MR ;
McDonald, RA ;
Bartosh, S ;
Ho, PL ;
Harmon, W .
PEDIATRIC TRANSPLANTATION, 2003, 7 (04) :321-335
[2]   Pediatric renal transplantation without steroids [J].
Birkeland, SA ;
Larsen, KE ;
Rohr, N .
PEDIATRIC NEPHROLOGY, 1998, 12 (02) :87-92
[3]   Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression [J].
Chakrabarti, P ;
Wong, HY ;
Scantlebury, VP ;
Jordan, ML ;
Vivas, C ;
Ellis, D ;
Lombardozzi-Lane, S ;
Hakala, TR ;
Fung, JJ ;
Simmons, RL ;
Starzl, TE ;
Shapiro, R .
TRANSPLANTATION, 2000, 70 (05) :760-764
[4]   Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) [J].
Dharnidharka, VR ;
Sullivan, EK ;
Stablein, DM ;
Tejani, AH ;
Harmon, WE .
TRANSPLANTATION, 2001, 71 (08) :1065-1068
[5]   Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry [J].
Fine, RN ;
Stablein, D .
PEDIATRIC NEPHROLOGY, 2005, 20 (03) :404-408
[6]  
Funch Donnie P, 2002, Recent Results Cancer Res, V159, P81
[7]   Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant [J].
Hymes, LC ;
Warshaw, BL .
PEDIATRIC TRANSPLANTATION, 2005, 9 (04) :520-522
[8]  
IROBERTI I, 1994, CLIN TRANSPLANT, V8, P405
[9]   New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable? [J].
Karin, M .
CELL, 1998, 93 (04) :487-490
[10]  
*NAPRTCS, 2005, 2005 ANN REP